Arena's Belviq scripts spike on DTC, stepped-up field force; Sanofi inks cancer marketing pact with India's Emcure;

> Arena Pharmaceuticals ($ARNA) reported a 43% rise in second-quarter sales of its obesity drug Belviq as DTC ads and a beefed-up sales force gained momentum. Report

> Sanofi ($SNY) tapped India's Emcure Pharmaceuticals to market its oncology drugs Taxotere, Jevtana, Fludara and Fasturtec in that country. Report

> It's official: Roche ($RHHBY) has won approval to market Avastin in Europe as a treatment for recurrent ovarian cancer resistant to platinum-based chemo. Release | Report

> Pfizer's ($PFE) Enbrel scored a European nod to treat a rare inflammatory joint disorder at early stages of the disease. Report

> Ashfield Healthcare recruited Wendy Wolf away from Publicis Touchpoint Solutions to be its SVP of commercial and clinical operations. Report

And Finally... A new scientific review found that aspirin could stave off bowel and stomach cancers. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.